The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1 in a fast-tracked 50-day review — the fastest for a new drug class since 2002. The daily pill is the first oral GLP-1 medication that can be taken any time of day without food or water restrictions, unlike Novo Nordisk's rival Wegovy pill which requires a 30-minute fast before meals.

In clinical trials, patients on the highest dose lost an average of 11.2% body weight over 72 weeks. While less potent than injectable options like Zepbound (21%) or Wegovy shots (15%), the convenience of a simple pill with no restrictions could drive mass adoption. Cash prices range from $149 to $349 per month, with insured patients potentially paying as low as $25 per month using a Lilly discount card.

Prescriptions are being accepted immediately via LillyDirect, with shipping starting April 6. The drug requires no cold-chain storage, simplifying distribution compared to injectables. Foundayo enters a rapidly growing market — Novo Nordisk's Wegovy pill has already garnered over 600,000 prescriptions since its December approval.